Shots: Novartis to receive $355M following the closure of acquisition, which is expected to occur in Q2’21. The acquisition expands existing Alcon’s ophthalmic portfolio and strengthens its footprints in the […]readmore
Tags : Exclusive
Shots: Lilly to receive up front, milestones, as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China SciNeuro to get an […]readmore
Shots: Sanofi to receive ~$353M including $2.25M up front and remaining as development, regulatory and commercial milestones as well as royalties on WW net sales of programs GBT gets exclusive […]readmore
Shots: The companies signed an exclusive license agreement to develop COVISHIELD + two mAb cocktail against emerging variants of SARS-CoV-2 including UK (B.1.1.7), South Africa (B.1.351), and Japan/Brazil (B.1.128) variants […]readmore
Shots: Takeda exercised its option to acquire Maverick for up to $525M up front as well as development and regulatory milestones including Takeda’s current equity stake and Maverick debt. The […]readmore
Shots: WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized from the panel Exelixis get […]readmore
Shots: Debiopharm to receive $226M up front, ~$853.7M as regulatory and commercial milestones along with royalties. The transaction is expected to close in early Q2’21 Merck KGaA get an exclusive […]readmore
Shots: Beijing Tide to receive up to $517.5M including up front, development, regulatory and sales milestone along with royalties and an option for a revenue-sharing arrangement for certain developed products […]readmore
Shots: Biomunex to receive up front, development, regulatory & sales milestones, equity investment along with royalties on sales of therapies Onward get the right to pursue development, manufacture & commercialize […]readmore
Shots: X-Chem to receive an up front and is eligible to receive research, development and regulatory milestone along with royalties on sales of therapies resulting from the collaboration Genentech will […]readmore